Free Trial
→ Your Bank Account Is No Longer Safe (From Priority Gold) (Ad)tc pixel

Short Interest in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Drops By 40.2%

Written by MarketBeat
September 8, 2025
ImmunoPrecise Antibodies logo with Medical background

Key Points

  • Short interest in ImmunoPrecise Antibodies Ltd. fell by 40.2% in August, decreasing from 725,300 shares to 433,700 shares.
  • Wall Street analysts upgraded the company's rating from "sell" to "hold," with an average consensus price target of $4.00.
  • The company reported a revenue of $5.06 million for the last quarter, missing consensus estimates significantly, which were $7.89 million.
  • MarketBeat previews top five stocks to own in October.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 15th, there was short interest totaling 433,700 shares, adeclineof40.2% from the July 31st total of 725,300 shares. Approximately1.1% of the shares of the company are sold short. Based on an average daily trading volume, of 2,750,000 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 2,750,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately1.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised ImmunoPrecise Antibodies from a "sell" rating to a "hold" rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $4.00.

Read Our Latest Analysis on IPA

Institutional Investors Weigh In On ImmunoPrecise Antibodies

Several hedge funds have recently modified their holdings of the business. XTX Topco Ltd lifted its position in shares of ImmunoPrecise Antibodies by 394.4% in the 2nd quarter. XTX Topco Ltd now owns 91,382 shares of the company's stock worth $97,000 after purchasing an additional 72,897 shares during the period. Ingalls & Snyder LLC lifted its position in shares of ImmunoPrecise Antibodies by 0.8% in the 2nd quarter. Ingalls & Snyder LLC now owns 2,779,363 shares of the company's stock worth $2,946,000 after purchasing an additional 21,236 shares during the period. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of ImmunoPrecise Antibodies in the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 6.70% of the company's stock.

ImmunoPrecise Antibodies Price Performance

The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.85 and a current ratio of 2.08. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $3.25. The company has a 50 day moving average price of $1.98 and a 200-day moving average price of $1.02. The firm has a market cap of $96.68 million, a P/E ratio of -3.08 and a beta of 0.53.

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.02). The company had revenue of $5.06 million during the quarter, compared to the consensus estimate of $7.89 million. ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative return on equity of 40.62%. Analysts expect that ImmunoPrecise Antibodies will post -0.27 EPS for the current fiscal year.

About ImmunoPrecise Antibodies

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ImmunoPrecise Antibodies Right Now?

Before you consider ImmunoPrecise Antibodies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.

While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.